Aurobindo Pharma Ltd

Mid Cap

Healthcare Sector

reflects a positive outlook for the share price

reflects a neutral outlook for the share price

reflects a negative outlook for the share price

The analysts information is for reference only and does not\n  represents an investment recommendation.

Analyst recommendation reflect the views of analysts who follow and write research reports.

Company Information is an introduction to the company’s business that details what it sell, how it was founded, what their mission is, how they manufacture or source their products, and why they serve customers.

Aurobindo Pharma is experiencing early signs of a market rebound after a corrective phase. Additionally, significant senior management changes were announced, effective November 2025.

Aurobindo Pharma Management Changes and Market Rebound - 04 Nov, 2025

Aurobindo Pharma has experienced a strong breakout, moving above key technical indicators, signaling a bullish trend. Traders are advised to enter long positions in the ₹1,120–₹1,140 range, targeting ₹1,245 with a stop-loss at ₹1,070.

Aurobindo Pharma Shows Bullish Momentum - 03 Nov, 2025

Aurobindo Pharma Ltd rose 1.15% today, marking its third consecutive session of gains. The stock is currently at Rs 1112, despite a 20.86% decline over the past year. The Nifty Pharma index has also shown positive movement, up 4.61% in the last month.

Aurobindo Pharma Sees Steady Gains Amid Market Trends - 29 Oct, 2025

Aurobindo Pharma has established a wholly-owned subsidiary, Eugia Pharma Chile SpA, to enhance its pharmaceutical presence in Chile, following its significant export revenue.

Aurobindo Pharma Expands into Chilean Market - 23 Oct, 2025

On October 9, pharma stocks, including Aurobindo Pharma, rose significantly after reports indicated the Trump administration might not impose tariffs on generic medicines, providing relief to Indian pharmaceutical companies.

Pharma Stocks Surge on Tariff Relief News - 09 Oct, 2025

Price to Earnings Ratio or Price to Earnings Multiple is the ratio of the share price of a stock to its earnings per share (EPS). It provides an indication of whether a stock at its current market price is expensive or cheap.

The price/earnings-to-growth ratio, or the PEG ratio, is a metric that helps investors value a stock by taking into account a company's market price, its earnings, and its future growth prospects.

Enterprise value (EV) is the total value of a company, defined in terms of its financing. It includes both the current share price (market capitalization) and the cost to pay off debt (net debt, or debt minus cash).

Alpha measures the amount that the investment has returned in comparison to the market index or other broad benchmark that it is compared against.

Beta measures a stock's volatility, the degree to which its price fluctuates in relation to the overall stock market. In other words, it gives a sense of the stock's risk compared to that of the greater market.

Dividend yield measures the quantum of earnings by way of total dividends that investors make by investing in that company.

The debt-to-total-assets ratio shows how much of a business is owned by creditors (people it has borrowed money from) compared with how much of the company's assets are owned by shareholders.

Operating cash flow (OCF) is a measure of the amount of cash generated by a company's normal business operations. Operating cash flow indicates whether a company can generate sufficient positive cash flow to maintain and grow its operations.

This widget shows the information about the stock's peers in consideration along with the different data for those peers so that the user can compare the stock with the other similar stock and invest accordingly.

Promoter holding is the amount of share of the company that is owned by the promoters. The promoters are the company's founders, who hold a majority stake in the company's capital.

A foreign institutional investor (FII) is an investor or investment fund investing in a country outside of the one in which it is registered or headquartered.

A mutual fund is a pool of money managed by a professional Fund Manager. It is a trust that collects money from a number of investors who share a common investment objective and invests the same in equities, bonds, money market instruments, and other securities.

Retail investors execute their trades through traditional or online brokerage firms or other types of investment accounts. Retail investors purchase securities for their own personal accounts and often trade in dramatically smaller amounts as compared to institutional investors.

This widget shows the bifurcation of stocks based on the percentage of stake with the different types of shareholders.

This widget will help value the stock based on the Price to Earning ratio of the stock and compare the valuation with the industry value and other similar stocks. It even shows the timeline of the valuation of the stock and its highest and lowest valuation over time.
A Time Series data is provided which compares the historical stock PE with Industry PE over the period of 5 years.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

In the last 7 days, AUROPHARMA stock has moved up by 5.4%

This section gives you an insight into the price movement of the stock for the last few quarters.

Price Rise

Mutual Funds have increased holdings from 18.96% to 19.30% in Sep 2025 quarter

This section gives you an insight into how the Mutual Funds Holding has changed for the stock over last few quarters.

MF Holding Up

In the last 3 years, Torrent Pharmaceuticals Ltd has given 117.7% return, outperforming this stock by 8.4%

This section gives you an insight into how the peers have performed as compared to this company in the last 3 years.

Against Peers

Promoters holdings remained unchanged at 51.82% of holdings in Sep 2025 quarter

This section gives you an insight into how the Promoter Holding has changed for the stock over the last few quarters.

Promoter Holding Unchanged

In the last 1 year, Divis Laboratories Ltd has given 15.3% return, outperforming this stock by 33.0%

This section gives you an insight into how the peers have performed as compared to this company in the last 1 year.

Retail Investor have decreased holdings from 6.87% to 6.38% in Sep 2025 quarter

This section gives you an insight into how the Retail Investors Holding has changed for the stock over last few quarters.

Retail Holding Down

Foreign Institutions have decreased holdings from 14.37% to 14.21% in Sep 2025 quarter

This section gives you an insight into how the FII Holding has changed for the stock over last few quarters.

FII Holding Down

Revenue is down for the last 2 quarters, 8.51K Cr → 7.97K Cr (in ₹), with an average decrease of 6.4% per quarter

This section gives you an insight into how the revenue of the company has moved for the last few quarters.

Revenue Fall

Netprofit is down for the last 2 quarters, 903.47 Cr → 824.75 Cr (in ₹), with an average decrease of 8.7% per quarter

This section gives you an insight into how the profit for the company has been for the last few quarters.

Profit Down

Nifty Midcap 50

BSE Healthcare

BSE 200

Nifty Midcap 150

S&P BSE 150 MidCap

S&P BSE 250 LargeMidCap

BSE Mid-Cap

Nifty LargeMidcap 250

NIFTY PHARMA

Nifty Healthcare

Nifty MidSmallcap 400

Nifty Midcap Sel

S&P BSE MidCap Select

Nifty 200

S&P BSE 400 MidSmallCap

Nifty Midcap 100

Nifty 500

BSE 500

HDFC Mid Cap Fund -Direct Plan - Growth Option

SBI Large & Midcap Fund Direct Growth

Quant Mid Cap Fund Growth Option Direct Plan

Quant ELSS Tax Saver Growth Option Direct Plan

ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth

Aurobindo Pharma shows signs of rebound, indicating potential for a directional breakout after a year-long corrective phase.

Aurobindo Pharma announces senior management changes, including resignations and retirements, effective November 2025.

Aurobindo Pharma Ltd’s net profit fell -10.28% since last year same period to ₹824.75Cr in the Q1 2025-2026. On a quarterly growth basis, Aurobindo Pharma Ltd has generated -8.71% fall in its net profits since last 3-months.

Name	Value	Action
MACD level (12,26)	1.43	Bullish
CCI (20)	231.35	Bearish
RSI (14)	71.05	Bearish
Momentum (10)	5.2	Bullish
ADI (14)	42.04	Bullish
Ultimate Oscillator (7,14,28)	48.99	Neutral

Name	Value	Action
SMA (20)	1144.6	Bullish
EMA (20)	1144.94	Bullish
VWMA (20)	1145.47	Bullish
SMA (50)	1142.24	Bullish
EMA (50)	1143.32	Bullish
SMA (200)	1143.53	Bullish
EMA (200)	1144.14	Bullish
KAMA (200)	1143.2	Bullish
DEMA (200)	1141.21	Bullish

Aurobindo Pharma Ltd (AUROPHARMA)

Summary

Overall

Oscillators

Moving Averages